• Evaxion added EVX-05, an off-the-shelf therapeutic vaccine program for glioblastoma, designed using its AI-Immunology platform.
• Candidate targets conserved endogenous retrovirus-derived antigens identified from patient tumor samples, aiming to broaden applicability across glioblastoma patients.
• Program moved into lead-candidate optimization, advancing toward initial clinical testing expected to be run with Duke University School of Medicine.
• Pipeline refocus included discontinuation of EVX-03; EVX-05 costs remain within existing budgets, keeping cash runway into 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-005577), on August 17, 2026, and is solely responsible for the information contained therein.